ストックスクリーナーアプリを入手
22.11
4.41%
-1.02
前日終値:
$23.13
開ける：
$23.15
24時間の取引高:
4.40M
Relative Volume:
0.38
時価総額：
$2.16B
収益：
$2.23B
当期純損益:
$-248.39M
株価収益率:
-8.2193
EPS:
-2.69
ネットキャッシュフロー:
$-697.55M
1週間 パフォーマンス:
-2.34%
1か月 パフォーマンス:
+28.40%
6か月 パフォーマンス:
-56.05%
1年 パフォーマンス:
-81.94%
1日の値動き範囲:
$22.09
$23.19
1週間の範囲:
$22.09
$25.32
52週間の値動き範囲:
$10.41
$138.81
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
名前
Sarepta Therapeutics Inc
セクター
電話
617-274-4000
住所
215 FIRST STREET, CAMBRIDGE, MA
SRPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
22.11 | 2.42B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-22 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 開始されました | Bernstein | Mkt Perform |
| 2025-07-29 | 繰り返されました | H.C. Wainwright | Sell |
| 2025-07-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2025-07-29 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-07-28 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-07-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 開始されました | Citigroup | Sell |
| 2025-07-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2025-07-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-07-21 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-07-21 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | ダウングレード | Mizuho | Outperform → Neutral |
| 2025-07-21 | ダウングレード | Needham | Hold → Underperform |
| 2025-07-21 | ダウングレード | UBS | Buy → Neutral |
| 2025-07-18 | ダウングレード | Needham | Buy → Hold |
| 2025-06-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-06-17 | 開始されました | Wolfe Research | Peer Perform |
| 2025-06-16 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-06-16 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | ダウングレード | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 開始されました | Wells Fargo | Overweight |
| 2025-04-02 | アップグレード | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-11-27 | 繰り返されました | Needham | Buy |
| 2024-11-25 | 開始されました | H.C. Wainwright | Sell |
| 2024-11-07 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 開始されました | Jefferies | Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-07-29 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-05-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Outperform |
| 2023-12-13 | 再開されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-11-21 | 開始されました | Wedbush | Outperform |
| 2023-10-31 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-04 | 開始されました | Citigroup | Buy |
| 2023-03-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 繰り返されました | BTIG Research | Buy |
| 2022-12-16 | アップグレード | UBS | Neutral → Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 繰り返されました | Needham | Buy |
| 2021-12-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-11-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-15 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-08-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-01-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-11 | ダウングレード | UBS | Buy → Neutral |
| 2021-01-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2021-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 開始されました | Mizuho | Buy |
| 2019-11-01 | 開始されました | Guggenheim | Buy |
| 2019-08-21 | 繰り返されました | Needham | Buy |
| 2019-07-09 | 繰り返されました | Morgan Stanley | Overweight |
| 2019-07-01 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-10-12 | 開始されました | Bernstein | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2018-09-14 | 再開されました | BofA/Merrill | Buy |
| 2018-09-06 | 開始されました | Credit Suisse | Outperform |
| 2018-08-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 繰り返されました | Robert W. Baird | Outperform |
| 2018-06-20 | 繰り返されました | Needham | Buy |
| 2018-06-19 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Sarepta Therapeutics Inc (SRPT) 最新ニュース
Sarepta Therapeutics Stock: Discounted Valuation Meets Breakthrough Pipeline (NASDAQ:SRPT) - Seeking Alpha
Will Sarepta Therapeutics Inc. stock see insider buyingShare Buyback & Accurate Entry and Exit Point Alerts - newser.com
Sarepta Crisis Reveals Valuable Leadership Tips for Executives - Bloomberg Law News
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com
November 28th Options Now Available For Sarepta Therapeutics (SRPT) - Nasdaq
Why (SRPT) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
How sentiment analysis helps forecast Sarepta Therapeutics Inc.July 2025 EndofMonth & Risk Controlled Stock Alerts - newser.com
Responsive Playbooks and the SRPT Inflection - news.stocktradersdaily.com
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo
Visualizing Sarepta Therapeutics Inc. stock with heatmapsCEO Change & High Return Trade Opportunity Guides - newser.com
(SRPT) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Trading Systems Reacting to (SRPT) Volatility - news.stocktradersdaily.com
Price-Driven Insight from (SRPT) for Rule-Based Strategy - news.stocktradersdaily.com
Jefferies reiterates Buy rating on Sarepta stock, maintains $35 price target - Investing.com India
What's Going On Sarepta Stock On Wednesday? - Benzinga
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up After Analyst Upgrade - MarketBeat
Sarepta (SRPT) Faces Medicaid Coverage Pause for Duchenne Treatm - GuruFocus
Royal Bank Of Canada Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $16.00 - MarketBeat
RBC Raises Price Target on Sarepta Therapeutics to $16 From $14, Keeps Sector Perform, Speculative Risk - MarketScreener
Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket - MSN
Sarepta suffers a setback as N.Y. panel recommends state Medicaid pause coverage of Duchenne drug - statnews.com
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
AAV Gene Therapy Market Size to Skyrocket at 40.1% CAGR by 2034 - GlobeNewswire Inc.
Avoiding Lag: Real-Time Signals in (SRPT) Movement - news.stocktradersdaily.com
The Technical Signals Behind (SRPT) That Institutions Follow - news.stocktradersdaily.com
(SRPT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Sarepta Therapeutics Shares Up Pre-Bell Ahead of Presentation of Data on Muscle Dystrophy Studies - MarketScreener
25,360 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by 111 Capital - MarketBeat
Sarepta Therapeutics (SRPT) Is Up 23.3% After FDA Lifts Elevidys Hold and Advances SRP-1003 Trial – Has The Bull Case Changed? - Sahm
Will Sarepta Therapeutics Inc. (AB3A) stock boost dividends furtherJuly 2025 Breakouts & Safe Capital Growth Tips - newser.com
How Sarepta Therapeutics Inc. stock benefits from strong dollar2025 Market Overview & AI Enhanced Execution Alerts - newser.com
Sarepta Therapeutics (SRPT) Valuation in Focus After FDA Clears Elevidys and Company Restructures - Sahm
(SRPT) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Sarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial Results - Yahoo Finance
(SRPT) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Sarepta: Q3 Earnings An Upcoming Catalyst, But Risks Undermine Any Contrarian Play (SRPT) - Seeking Alpha
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress - Placera.se
Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained! - ts2.tech
Sarepta Therapeutics (SRPT) Receives Sell Rating Amid Declining Growth - GuruFocus
Trading the Move, Not the Narrative: (SRPT) Edition - news.stocktradersdaily.com
Using RSI to spot recovery in Sarepta Therapeutics Inc.Weekly Trend Summary & AI Forecasted Stock Moves - newser.com
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Why Sarepta Therapeutics Inc. (AB3A) stock could rally stronglyProduct Launch & Accurate Buy Signal Alerts - newser.com
Liquidity Mapping Around (SRPT) Price Events - news.stocktradersdaily.com
Sarepta Therapeutics (NASDAQ:SRPT) Trading Up 10.4%What's Next? - MarketBeat
Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday - Benzinga
(SRPT) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
How (SRPT) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
How Sarepta Therapeutics Inc. (AB3A) stock moves in volatile trading sessionsQuarterly Portfolio Review & Safe Swing Trade Setups - newser.com
How higher bond yields impact Sarepta Therapeutics Inc. (AB3A) stockJuly 2025 Retail & Verified Momentum Stock Watchlist - newser.com
Can Sarepta Therapeutics Inc. stock sustain institutional interest2025 Short Interest & Community Trade Idea Sharing - newser.com
Sarepta Therapeutics Inc (SRPT) 財務データ
収益
当期純利益
現金流量
EPS
Sarepta Therapeutics Inc (SRPT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Barry Richard | Director |
May 16 '25 |
Option Exercise |
32.63 |
12,350 |
402,981 |
2,966,667 |
| Barry Richard | Director |
May 13 '25 |
Option Exercise |
19.23 |
20,246 |
389,359 |
2,954,317 |
| Nicaise Claude | Director |
Mar 12 '25 |
Option Exercise |
25.18 |
9,746 |
245,404 |
30,303 |
| Nicaise Claude | Director |
Mar 12 '25 |
Sale |
99.64 |
2,491 |
248,203 |
27,812 |
5.74%
大文字化:
|
ボリューム (24 時間):